Celularity (NASDAQ:CELUW – Get Free Report) is anticipated to issue its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($1.50) per share for the quarter.
Celularity Stock Performance
Celularity stock opened at $0.01 on Tuesday. Celularity has a fifty-two week low of $0.01 and a fifty-two week high of $0.10. The firm’s 50-day simple moving average is $0.01 and its 200 day simple moving average is $0.02.
About Celularity
Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.
The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.
Read More
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
